A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Clinical trial NCT07678593 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07678593
Sponsor: Genfleet Therapeutics (Shanghai) Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors Cancer Pancreatic Ductal Adenocarcinoma RAS Mutation

Start date: 2026-09-01
Primary completion: 2027-11-01
Enrollment: 222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.